[go: up one dir, main page]

WO2008105392A1 - Dérivé de 3-amino-2-indolyl-butyrolactame, son procédé de production et agent pharmaceutique le comprenant en tant que principe actif - Google Patents

Dérivé de 3-amino-2-indolyl-butyrolactame, son procédé de production et agent pharmaceutique le comprenant en tant que principe actif Download PDF

Info

Publication number
WO2008105392A1
WO2008105392A1 PCT/JP2008/053255 JP2008053255W WO2008105392A1 WO 2008105392 A1 WO2008105392 A1 WO 2008105392A1 JP 2008053255 W JP2008053255 W JP 2008053255W WO 2008105392 A1 WO2008105392 A1 WO 2008105392A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
indolylbutyrolactam
derivative
amino
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053255
Other languages
English (en)
Japanese (ja)
Inventor
Mikiko Sodeoka
Tadashi Shimizu
Kosuke Dodo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Publication of WO2008105392A1 publication Critical patent/WO2008105392A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne une substance pour inhiber la mort cellulaire, qui est efficace en tant qu'agent prophylactique ou thérapeutique pour la progression d'un état d'une maladie dont la progression ou l'exacerbation est associée à la mort cellulaire. Cette invention concerne spécifiquement : un composé représenté par la formule générale (1) et l'un de ses sels acceptables sur le plan pharmaceutique; et une application d'utilisation associée à une activité d'inhibition de la mort cellulaire du composé.
PCT/JP2008/053255 2007-02-27 2008-02-26 Dérivé de 3-amino-2-indolyl-butyrolactame, son procédé de production et agent pharmaceutique le comprenant en tant que principe actif Ceased WO2008105392A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007047932A JP2008208086A (ja) 2007-02-27 2007-02-27 ３−アミノ−２−インドリルブチロラクタム誘導体、その製造法、及びこれを有効成分とする医薬
JP2007-047932 2007-02-27

Publications (1)

Publication Number Publication Date
WO2008105392A1 true WO2008105392A1 (fr) 2008-09-04

Family

ID=39721223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053255 Ceased WO2008105392A1 (fr) 2007-02-27 2008-02-26 Dérivé de 3-amino-2-indolyl-butyrolactame, son procédé de production et agent pharmaceutique le comprenant en tant que principe actif

Country Status (2)

Country Link
JP (1) JP2008208086A (fr)
WO (1) WO2008105392A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101098583B1 (ko) * 2008-01-04 2011-12-26 주식회사 엘지생명과학 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042100A1 (fr) * 1998-02-23 1999-08-26 Sagami Chemical Research Center Inhibiteurs de la mort cellulaire
WO2001013916A1 (fr) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Medicaments inhibant la mort cellulaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042100A1 (fr) * 1998-02-23 1999-08-26 Sagami Chemical Research Center Inhibiteurs de la mort cellulaire
WO2001013916A1 (fr) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Medicaments inhibant la mort cellulaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DODO K. ET AL.: "Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives", BIOORG. MED. CHEM. LETT., vol. 15, no. 12, 2005, pages 3114 - 3118, XP004915608 *

Also Published As

Publication number Publication date
JP2008208086A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
WO2010136474A3 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
WO2010122980A8 (fr) Nouvel agoniste du récepteur ss de l'hormone thyroïdienne
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
NO20092033L (no) Nye forbindelser
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2010098600A3 (fr) Dérivés d'azole substitués, composition pharmaceutique contenant les dérivés et procédé de traitement de la maladie de parkinson à l'aide de ceux-ci
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
WO2009071480A3 (fr) Dérivés de dihydroptéridin-6-one substitués, procédé de préparation desdits dérivés et leur utilisation en tant qu'inhibiteurs de kinase
UA97351C2 (ru) Производная кумарина, имеющая противоопухолевую активность
WO2006098918A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
WO2009051119A1 (fr) Composé de pyrimidylindoline
WO2007135527A3 (fr) Composés de benzimidazolyle
EP2639229A3 (fr) Dérivé de thiazole et son utilisation en tant qu'inhibiteur VAP-1
WO2009030952A3 (fr) Composés hétérocycliques et leurs procédés d'utilisation
WO2009041663A1 (fr) Agent destiné à la prévention et/ou au traitement de maladies cutanées
WO2011025982A3 (fr) Composés tétracycline
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
WO2011009714A3 (fr) Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux
WO2009003719A3 (fr) Dérivés d'indane-amine, leur préparation et leur utilisation comme médicaments
WO2010132670A3 (fr) Composés pentacyclines
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007009721A3 (fr) Derives de pyrazoline substitues indoline, preparation et utilisation comme medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711979

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711979

Country of ref document: EP

Kind code of ref document: A1